Forest wins over generic on Lexapro patent

New York, July 13 - Forest Laboratories, Inc. said the U.S. District Court for the District of Delaware determined that the U.S. patent covering escitalopram, the active ingredient in Lexapro, is both valid, enforceable and infringed by Teva Pharmaceutical Industries Ltd.'s proposed generic product.

Forest said the decision confirms the patent rights of itself and H. Lundbeck A/S for Lexapro which expire in March 2012.

Forest is a New York-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.